Research programme: small molecule therapeutics - Boehringer Ingelheim/Evotec SE
Alternative Names: CB2 receptor agonists - Boehringer Ingelheim/Evotec SE; Enzyme modulators - Boehringer Ingelheim/Evotec SE; GPCR modulators - Boehringer Ingelheim/Evotec SE; Ion channel modulators - Boehringer Ingelheim/Evotec SELatest Information Update: 25 Sep 2019
At a glance
- Originator Boehringer Ingelheim; Evotec AG
- Developer Boehringer Ingelheim; Evotec NeuroSciences; Evotec SE
- Class Benzylamines; Small molecules; Sulfonamides
- Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Metabolic disorders
- No development reported Cancer; Cardiovascular disorders; CNS disorders; Immunological disorders; Inflammation; Pain; Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Germany